A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

NCT06563804 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)/AML
Chronic Myelomonocytic Leukemia (CMML)

Interventions

DRUG: S227928
DRUG: Venetoclax

Sponsor

Servier Bio-Innovation LLC